Drug intelligence / Profile preview

Bsense tinnitus program

Development stage: Preclinical
Lead developer: Bsense Bio Therapeutics
Modality: Small Molecules

Overview

Bsense Bio Therapeutics is developing a small molecule dual ion-channel modulator for the treatment of tinnitus. The therapeutic approach involves the simultaneous inhibition of the Transient Receptor Potential Vanilloid 1 (TRPV1) channel and the activation of Potassium Voltage-Gated Channel Subfamily Q Member 2/3 (Kv7.2/3) channels. These channels are co-localized on sensory neurons, and the dual modulation is designed to dampen neuronal hyperexcitability associated with sensory disorders like tinnitus. While the company's lead asset, BSEN760, is in clinical development for chronic pain, the tinnitus program is currently in the preclinical stage.

Other names: TRPV1-Kv7.2/3 dual modulator (tinnitus)

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)KCNQ4 (Potassium channel subfamily KQT member 4)

Beyond the preview

Go deeper on Bsense tinnitus program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bsense tinnitus program.

Explore the full profile